Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease
US10995118B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10995118-B2 |
| Application number | US-201415022749-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 23, 2014 |
| Priority date | Sep 26, 2013 |
| Publication date | May 4, 2021 |
| Grant date | May 4, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A peptide comprising an amino acid sequence which binds to amyloid beta species and in which the negative charge of its free C-terminus carboxyl group was removed by modification such that no charge or a positive charge is present at said free C-terminus, wherein the amino acid sequence is SEQ ID NO: 12, and wherein the free C-terminus carboxyl group is replaced with an acid amide group (CONH2 group), a COH group, a CONH-alkyl group or a CONH-alkyl amine group, and wherein the peptide's binding affinity to the amyloid beta species is increased as compared to an analogous peptide without the C-terminus modification.
Assignees
Inventors
Classifications
Alzheimer · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10995118B2 cover?
- Amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.
- Who is the assignee on this patent?
- Forschungszentrum Juelich Gmbh
- What technology area does this patent fall under?
- Primary CPC classification C07K7/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).